Sep 28 2023 |
A Second Chance to Win Your Government Healthcare Contract |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 8 2023 |
OIG General Compliance Program Guidance November 2023 |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 21 2023 |
Pharmaceutical Companies Have Rights if the Federal Government Seized their Patents |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 25 2024 |
PFAS in Food Packaging: The Beginning of the End? |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 2 2020 |
Eleventh Hour Rulemaking: HHS Eliminates Safe Harbor Protections for PBM Drug Rebates; and Creates Two New Safe Harbors for Point-of-Service Discounts and PBM Fixed-Fee Arrangements |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 29 2021 |
NLRB’s Division of Advice Determines Certain Workers in the Cannabis Industry Are Exempt From Federal Labor Law |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 29 2011 |
A MATRIXX Revolution, Part II: Supreme Court affirms Ninth Circuit's holding that Life Science Companies Cannot Rely On a Statistical Significance Standard When Deciding Whether Adverse Event Reports are Material for the Purpose of Securities Disclosures |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 20 2017 |
California Court of Appeal Affirms Judgment Finding No Duty to Defend Drug Manufacturer in Lawsuits Alleging Increased Opioid Usage |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 11 2013 |
Farming Solar Rays: County Decision to Approve Industrial-Scale Solar on Williamson Act Lands OK'd |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 25 2021 |
AB-45: California Finally Welcomes Hemp Products To The Marketplace |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 7 2013 |
California Passes Landmark Green Chemical Laws |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 20 2018 |
Federal Antitrust Regulators Approve Cigna’s Proposed Acquisition of Express Scripts |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 7 2022 |
FDA Releases Guidance for Digital Health Tech Used in Clinical Investigations |
Sheppard, Mullin, Richter & Hampton LLP |
May 31 2014 |
Developer-Prepared Cost Comparisons Can Show Economic Infeasibility Under CEQA - California Environmental Quality Act |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 19 2019 |
FDA Update: Recent Trends and a New Regime |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 3 2014 |
Agricultural Cooperative Antitrust Litigation Continues to Mushroom |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 5 2015 |
New FDA Draft Guidance on REMS and Bioequivalence Studies: Does New Procedure Secure ANDA Applicants The Right to Obtain Samples? |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 2 2022 |
Proposal to Overhaul Privacy Law Governing Substance Use Disorder Treatment Records |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 20 2022 |
Comment Period for “Healthy” Regulations Extended; But Consumer Class Actions Targeting “Health Halos” May Continue |
Sheppard, Mullin, Richter & Hampton LLP |
May 25 2023 |
Florida Bans Offshoring of Certain Patient Information |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 22 2023 |
Connecticut Governor Signs Health Care Legislation to Reduce Costs and Increase Competition |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 14 2020 |
Day 1 Notes at the 2020 J.P. Morgan Healthcare Conference |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 28 2020 |
Federal Circuit Changes the Game for Selling Single-API Drugs to the Government |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 6 2020 |
CMS “Hospitals Without Walls” Waiver: Looking To ASCs to Provide Relief |
Sheppard, Mullin, Richter & Hampton LLP |
May 15 2020 |
Not So Fast – FDA Retracts Authorization for Some Respirators Made in China |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 31 2024 |
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 30 2020 |
A Year of Living Dangerously: 2020 and Maneuvers on the 340B Drug Pricing Program Battlefield |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 11 2020 |
It’s Not Pop Secret, Ninth Circuit Affirms that Plaintiff Didn’t Have a Leg to Stand On |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 2 2010 |
US Patent Office Expands Green Technology Accelerated Examination Program - More categories of invention are now eligible for expedited processing |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 8 2011 |
The Tax Relief, Unemployment Insurance Reauthorization and Job Creation Act of 2010 and its effect on the Energy Sector |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 11 2017 |
Texas Telemedicine Saga Finally Over? The Texas Medical Board Substantially Revises Telemedicine Regulations |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 19 2011 |
Taking a Cue From Brazil's Sustainable Development Practices Past and Present |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 30 2021 |
San Francisco Passes Measure Requiring Sick Leave for Domestic Workers – “First of Its Kind” |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 10 2013 |
New “Potentially Feasible” Alternative Does Not Trigger Draft Environmental Impact Report (EIR) Recirculation Unless Considered “Significant New Information”; No Findings Needed to Reject Alternative As Infeasible |
Sheppard, Mullin, Richter & Hampton LLP |
May 17 2022 |
California Cannabis Farmers May Finally Get Some Relief |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 26 2022 |
New Litigation Continues to Challenge the Social Equity and Scoring Process of the Illinois Cannabis Regulation And Tax Act |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 12 2015 |
Interface without Regulation – FDA Deregulates MDDS and Related Technologies |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 28 2022 |
Federal Judge in NY Issues Preliminary Injunction to Block Retail Cannabis Licenses on Constitutional Grounds |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 10 2015 |
NDRC Issued Opinions and Notice on Drug Price Reform: National Development and Reform Commission |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 25 2023 |
No Surprises Act Update: Certified IDR Entities to Resume Payment Determinations for Services Furnished Before October 25, 2022 |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 11 2023 |
“Dietary Guidance Statements” in Food Labeling: What You Need to Know About FDA’s Latest Draft Guidance for the Food Industry |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 24 2023 |
Regulators Send Warning Letter to Hospitals and Telehealth Providers About Tracking Technology Use |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 12 2020 |
Federal Circuit Revolutionizes Country of Origin Analysis for Pharmaceuticals |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 31 2020 |
Personal Protective Equipment & Ventilators: How FDA Is Increasing Supply for the US Healthcare System |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 18 2023 |
FDA’s Proposed Rule on LDT Regulation and the Debate over Agency Deference |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 23 2020 |
FDA Issue Guidance on Manufacturing Drugs, APIs during COVID-19 |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 11 2024 |
China Semiconductor Export Regulations, Episode V – Updates and Corrections to the Advanced Computing and Semiconductor Regulations |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 9 2010 |
EPA Proposes 'Veto' of Section 404 Permit for Mountaintop Removal Coal Mining Project in West Virginia |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 12 2011 |
California Court Issues Tentative Ruling Enjoining AB 32 Implementation |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 10 2018 |
Notes on Day 2 of the JP Morgan Healthcare Conference |
Sheppard, Mullin, Richter & Hampton LLP |